The above findings demonstrate that BRAF600E mediates ERK activation and Mcl-1 stabilization downstream of PI3K, and predict that targeting any node in this pathway sensitizes colon cancer cells to Everolimus-induced apoptosis. Here, MCL1 is linked to malignant colon neoplasm.